From Fatigued to Fantastic!

by Jacob Teitelbaum

  6. S. E. Straus, S. Fritz, J. K. Dale, et al., “Lymphocyte Phenotype and Function in the Chronic Fatigue Syndrome,” Journal of Clinical Immunology 13 (1) (January 1993): 30–40.

  7. J. E. Teitelbaum and B. Bird, “Effective Treatment of Severe Chronic Fatigue: A Report of a Series of 64 Patients,” Journal of Musculoskeletal Pain 3 (4) (1995): 91–110.

  8. F. Wolfe et al., “The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia: Report of the Multicenter Criteria Committee,” Arthritis and Rheumatology 33 (1990): 160–172.

  9. J. E. Teitelbaum, B. Bird, A. Weiss, et al., “Effective Treatment of CFS and FMS: A Randomized, Double-Blind Placebo Controlled Study,” Journal of Chronic Fatigue Syndrome 8 (2) (2001): 3–24.

  10. J. G. Travell and D. G. Simons, Myofascial Pain and Dysfunction: The Trigger Point Manual, Vol. 1 (Baltimore, MD: Williams & Wilkins, 1983), pp. 103–164.

  11. M. A. Demitrack, K. Dale, S. E. Straus, et al., “Evidence for Impaired Activation of the Hypothalamic-Pituitary-Adrenal Axis in Patients with Chronic Fatigue Syndrome.” Journal of Clinical Endocrinology and Metabolism 73 (6) (December 1991): 1223–1234.

  12. J. E. Teitelbaum, “Estrogen and Testosterone in CFIDS/FMS,” From Fatigued to Fantastic! newsletter, February 1997.

  13. P. O. Behan, “Post-Viral Fatigue Syndrome Research,” in The Clinical and Scientific Basis of Myalgic Encephalitis and Chronic Fatigue Syndrome, ed. Byron Hyde, Jay Goldstein, and Paul Levine (Ottawa, Ontario, Canada: Nightingale Research Foundation, 1992), p. 238.

  14. J. E. Teitelbaum, “Mitochondrial Dysfunction [in CFS/FMS],” From Fatigued to Fantastic! newsletter 1 (2) (1997).

  15. T. Brockow et al., “A Randomized Controlled Trial on the Effectiveness of Mild Water-filtered Near Infrared Whole-body Hyperthermia as an Adjunct to a Standard Multimodal Rehabilitation in the Treatment of Fibromyalgia,” Clin J Pain, January 1, 2007; 23 (1): 67–75.

  16. D. Halpin and S. Wessely, “VP-1 Antigen in Chronic Postviral Fatigue Syndrome,” The Lancet 1 (8645) (6 May 1989): 1028–1029.

  17. G. E. Yousef, E. J. Bell, G. F. Mann, et al., “Chronic Enterovirus Infection in Patients with Postviral Fatigue Syndrome,” The Lancet 1 (8578) (23 January 1988): 146–147.

  18. L. E. Archard, N. E. Bowles, P. O. Behan, et al., “Postviral Fatigue Syndrome Persistence of Enterovirus RNA in Muscle and Elevated Creatine Kinase,” Journal of the Royal Society of Medicine 81 (6) (June 1988): 326–329.

  19. A. Martin Lerner, M. Zervos, and H. J. Dworkin, “New Cardiomyopathy: Pilot Study of Intravenous Ganciclovir in a Subset of the Chronic Fatigue Syndrome,” Infectious Diseases in Clinical Practice 6 (1997): 110–117.

  20. G. L. Nicolson, “Considerations When Undergoing Treatment for Chronic Infections Found in Chronic Fatigue Syndrome, Fibromyalgia, and Gulf War Illness,” Journal of Internal Medicine 1 (1988): 115–117, 123–128.

  21. G. L. Nicolson, M. Y. Nasralla, J. Haier, et al., “Mycoplasmal Infections in Chronic Illness: Fibromyalgia and Chronic Fatigue Syndrome, Gulf War Illness, Human Immunodeficiency Virus, and Rheumatoid Arthritis,” Medical Sentinel 4 (1999): 172–176.

  22. J. Brewer, K. K. Knox, and D. R. Carrigan, “Longitudinal Study of Chronic Active HHV-6 Viremia in Patients with CFS,” paper presented at IDSA Conference, Philadelphia, PA, November 1999.

  23. D. Wakefield, A. Lloyd, J. Dwyer, et al., “Human Herpesvirus 6 and Myalgic Encephalomyelitis,” The Lancet 1 (8593) (7 May 1988): 1059.

  24. Byron Hyde, Jay Goldstein, and Paul Levine, eds., The Clinical and Scientific Basis of Myalgic Encephalitis and Chronic Fatigue Syndrome (Ottawa, Ontario, Canada: Nightingale Research Foundation, 1992).

  25. W. Jefferies, Safe Uses of Cortisol, monograph (Springfield, IL: Charles C. Thomas, 1981).

  26. C. A. Everson, “Sustained Sleep Deprivation Impairs Host Defense,” American Journal of Physiology 265 (5 Part 2) (November 1993): R1148–1154.

  27. S. Pillemer, L. A. Bradley, L. J. Crofford, et al., “The Neuroscience and Endocrinology of FMS—[An NIH] Conference Summary,” Arthritis and Rheumatism 40 (11) (November 1997): 1928–1939.

  28. H. Moldofsky, “Sleep and Chronic Fatigue Syndrome,” in Chronic Fatigue Syndrome, ed. D. Dawson and S. Sabin (Boston, MA: Little, Brown and Company, 1993).

  29. F. Wolfe, K. Ross, J. Anderson, I. J. Russell, and L. Hebert, “The Prevalence and Characteristics of Fibromyalgia in the General Population,” Arthritis Rheum 1995 January; 38 (1): 19–28.

  30. L. Lindell, S. Bergman, I. F. Petersson, L. T. Jacobsson, and P. Herrstrom, “Prevalence of Fibromyalgia and Chronic Widespread Pain.” Scand J Prim Health Care 2000 September; 18 (3): 149–153.

  31. M. Matucci Cerinic, M. Zoppi, C. Taieb, J. Caubere, G. Hamelin, and C. Schmitt, “Prevalence of Fibromyalgia in Italy: Updated Results,” Annals of the Rheumatic Diseases 2006; 65 (supplement 2): 555.

  32. M. Guermazi, S. Ghroubi, M. Sellami, M. Elleuch, E. André, C. Schmitt, C. Taieb, J. Damak, and M. Elleuch, “Epidemiology of Fibromyalgia in Tunisia,” Annals of the Rheumatic Diseases 2006; 65 (supplement 2): 553.

  33. V. Cobankara, Ö. Ünal, M. Öztürk, and A. Bozkurt, “The Prevalence of Fibromyalgia Among Textile Workers in the City of Denizli in Turkey,” Annals of the Rheumatic Diseases 2006; 65 (supplement 2): 554.

  34. C. Schmitt, M. Spaeth, E. André, J. Caubere, and C. Taieb, “Fibromyalgia Syndrome: A German Epidemiological Survey,” Annals of the Rheumatic Diseases 2006; 65 (supplement 2): 554.

  Chapter 2. Create Your Individual Treatment Protocol—Beginning with Ribose for Energy Production

  1. J. E. Teitelbaum and B. Bird, “Effective Treatment of Severe Chronic Fatigue: A Report of a Series of 64 Patients,” Journal of Musculoskeletal Pain 3 (4) (1995): 91–110.

  2. Ibid.

  3. D. C. Vernon et al., “Preliminary Evidence of Mitochondrial Dysfunction Associated with Postinfective Fatigue After Acute Infection with Epstein-Barr Virus,” BMC Infectious Diseases 2006, 6; 15 doi: 10.1186/1471–2334–6–15, 31 January 2006, http://www.biomedcentral.com/1471–2334/6/15/abstract.

  4. J. Eisinger, A. Plantamura, and T. Ayavou, “Glycolysis Abnormalities in Fibromyalgia,” Journal of the American College of Nutrition 1994; 13 (2): 144–148.

  5. A. Bengtsson, and K. G. Henriksson, “The Muscle in Fibromyalgia—A Review of Swedish Studies,” Journal of Rheumatology Supplement 1989; 19: 144–149.

  6. N. Lund, A. Bengtsson, and P. Thorborg, “Muscle Tissue Oxygen in Primary Fibromyalgia,” Scandinavian Journal of Rheumatology 1986; 15 (2): 165–173.

  7. E. S. Strobl, M. Krapf, M. Suckfull, W. Bruckle, W. Fleckenstein, and W. Muller, “Tissue Oxygen Measurement and 31P Magnetic Resonance Spectroscopy in Patients with Muscle Tension and Fibromyalgia,” Rheumatology International 1997; 16 (5): 175–180.

  8. F. Douche-Aourik, W. Berlier, L. Feasson, T. Bourlet, R. Harrath, S. Omar, F. Grattard, C. Denis, and B. Pozzetto, “Detection of Enterovirus in Human Muscle from Patients with Chronic Inflammatory Muscle Disease or Fibromyalgia and Healthy Subjects,” Journal of Medical Virology 2003; 71 (4): 540–547.

  9. J. H. Park, P. Phothimat, C. T. Oates, M. Hernanz-Schulman, N. J. Olson, “Use of P-31 Magnetic Resonance Spectroscopy to Detect Metabolic Abnormalities in Muscles of Patients with Fibromyalgia,” Arthritis and Rheumatology 1998; 41 (3): 406–413.

  10. M. J. Kushmerick, “Muscle Energy Metabolism, Nuclear Magnetic Resonance Spectroscopy and Their Potential in the Study of Fibromyalgia,” Journal of Rheumatology [supplement] 1989; 19: 40–46.

  11. A. Bengtsson, K. G. Henriksson, and J. Larsson, “Reduced High-Energy Phosphate Levels in the Painful Muscles of Patients with Primary Fibromyalgia,” Arthritis and Rheumatology 1986; 29 (7): 817–821.

  12. E. Lund, S. A. Kendall, B. Janerot-Sjoberg, and A. Bengtsson, “Muscle Metabolism in Fibromyalgia Studied by P-31 Magnetic Resonance Spectroscopy During Aerobic and Anaerobic Exercise,” Scandinavian Journal of Rheumatology 2003; 32 (3): 138–145.

&
nbsp; 13. J. Eisinger, D. Bagneres, P. Arroyo, A. Plantamura, and T. Ayavou, “Effects of Magnesium, High-Energy Phosphates, Piracetam and Thiamin on Erythrocyte Transketolase,” Magnetic Research 1994; 7 (1): 59–61.

  14. S. Jacobsen, K. E. Jensen, C. Thomsen, B. Danneskiold-Samsoe, and O. Henriksen, “Magnetic Resonance Spectroscopy in Fibromyalgia: A Study of Phosphate-31 Spectra from Skeletal Muscles During Rest and After Exercise,” Ugeskr Laeger 1994; 156 (46): 6841–6844.

  15. N. J. Olson and J. H. Park, “Skeletal Muscle Abnormalities in Patients with Fibromyalgia,” American Journal of Medical Science 1998; 315 (6): 351–358.

  16. K. G. Henriksson, “Muscle Pain in Neuromuscular Disorders and Primary Fibromyalgia,” Neurologija 1989; 38 (3): 213–221.

  17. M. W. Krapf, S. Muller, P. Mennet, T. Stratz, W. Samborski, and W. Muller, “Recording Muscle Spasms in the Erector Spinae Using in Vivo 31P Magnetic Resonance Spectroscopy in Patients with Chronic Lumbalgia and Generalized Tendomyopathies,” Z Rheumatology 1992; 51 (5): 229–237.

  18. P. O. Behan, “Post-Viral Fatigue Syndrome Research,” in The Clinical and Scientific Basis of Myalgic Encephalitis and Chronic Fatigue Syndrome, eds. Byron Hyde, Jay Goldstein, and Paul Levine (Ottawa, Ontario, Canada: Nightingale Research Foundation, 1992), p. 238.

  19. J. E. Teitelbaum, J. A. St. Cyr, and C. Johnson, “The Use of D-ribose in Chronic Fatigue Syndrome and Fibromyalgia: A Pilot Study,” J Alternative and Complementary Medicine 2006; 12 (9): 857–862.

  20. Y. Hellsten, L. Skadgauge, and J. Bangsbo, “Effect of Ribose Supplementation on Resynthesis of Adenine Nucleotides After Intense Intermittent Training in Humans,” American Journal of Physiology 2004; 286 (1): R182–R188.

  21. P. C. Tullson and R. L. Terjung, “Adenine Nucleotide Synthesis in Exercising and Endurance-Trained Skeletal Muscle,” American Journal of Physiology 1991; 261: C342–C347.

  22. J. J. Brault and R. L. Terjung, “Purine Salvage to Adenine Nucleotides in Different Skeletal Muscle Fiber Types,” Journal of Applied Physiology 2001; 91: 231–238.

  23. B. Gebhart and J. A. Jorgenson, “Benefit of Ribose in a Patient with Fibromyalgia,” Pharmacotherapy 2004; 24 (11): 1146–1648.

  24. J. S. Ingwall, ATP and the Heart (Boston, MA: Kluwer Academic Publishers).

  25. D. Reibel and M. Rovetto, “Myocardial ATP Synthesis and Mechanical Function Following Oxygen Deficiency,” American Journal of Physiology 1978; 234 (5): H620–H624.

  26. H. G. Zimmer, H. Ibel, and U. Suchner, “Ribose Intervention in the Cardiac Pentose Phosphate Pathway Is Not Species-Specific,” Science 1984; 223: 712–714.

  27. H. Omran, S. Illien, D. MacCarter, J. A. St. Cyr, and B. Luderitz, “D-Ribose Improves Diastolic Function and Quality of Life in Congestive Heart Failure Patients: A Prospective Feasibility Study,” European Journal of Heart Failure 2003; 5: 615–619.

  28. N. Vijay, D. MacCarter, M. Washam, and J. St. Cyr, “Ventilatory Efficiency Improves with D-Ribose in Congestive Heart Failure Patients,” Journal of Molecular and Cellular Cardiology 2005; 38 (5): 820.

  29. O. Carter, D. MacCarter, S. Mannebach, J. Biskupiak, G. Stoddard, E. M. Gilbert, and M. A. Munger, “D-Ribose Improves Peak Exercise Capacity and Ventilatory Efficiency in Heart Failure Patients,” Journal of the American College of Cardiology 2005; 45 (3 supplement A): 185A.

  30. J. C. Griffiths, J. F. Borzelleca, and J. St. Cyr, “Lack of Oral Embryotoxicity/Teratogenicity with D-Ribose in Wistar Rats,” Journal of Food and Chemical Toxicology 2007; 45 (3): 388–395.

  31. J. C. Griffiths, J. F. Borzelleca, and J. St. Cyr, “Sub-Chronic (13-Week) Oral Toxicity Study with D-Ribose in Wistar Rats,” Journal of Food and Chemical Toxicology 2007; 45 (1): 144–152.

  32. M. Gross, B. Dormann, and N. Zollner, “Ribose Administration During Exercise: Effects on Substrates and Products of Energy Metabolism in Healthy Subjects and a Patient with Myoadenylate Deaminase Deficiency,” Klin Wochenschr 1991; 69: 151–155.

  33. D. R. Wagner, U. Gresser, and N. Zollner, “Effects of Oral Ribose on Muscle Metabolism During Bicycle Ergometer in AMPD-Deficient Patients,” Annals of Nutrition and Metabolism 1991; 35: 297–302.

  34. M. Gross, S. Reiter, and N. Zollner, “Metabolism of D-Ribose Administered to Healthy Persons and to Patients with Myoadenylate Deaminase Deficiency,” Klin Wochenschr 1989; 67: 1205–1213.

  35. E. K. Guymer and K. J. Clauw, “Treatment of Fatigue in Fibromyalgia,” Rheum Dis Clin North Am 2002; 28 (2): 67–78.

  36. D. S. Rooks, C. B. Silverman, and F. G. Kantrowitz, “The Effects of Progressive Strength Training and Aerobic Exercise on Muscle Strength and Cardiovascular Fitness in Women with Fibromyalgia: A Pilot Study,” Arthritis Rheum 2002; 47 (1): 22–28.

  37. R. Geenen, J. W. Jacobs, and J. W. Bijlsma, “Evaluation and Management of Endocrine Dysfunction in Fibromyalgia,” Rheum Dis Clin North Am 2002; 28 (2): 389–404.

  38. C. L. Schachter, A. J. Busch, P. M. Peloso, and M. S. Shepard, “Effects of Short Versus Long Bouts of Aerobic Exercise in Sedentary Women with Fibromyalgia: A Randomized Controlled Trial,” Phys Ther 2003; 83 (4): 340–358.

  39. D. L. Williamson, P. M. Gallagher, M. P. Goddard, and S. W. Trappe, “Effects of Ribose Supplementation on Adenine Nucleotide Concentration in Skeletal Muscle Following High-Intensity Exercise,” Med Sci Sport Exc 2001; 33 (5 supplement).

  40. N. Zollner, S. Reiter, M. Gross, D. Pongratz, C. D. Reimers, K. Gerbitz, I. Paetzke, T. Deufel, and G. Hubner, “Myoadenylate Deaminase Deficiency: Successful Symptomatic Therapy by High-Dose Oral Administration of Ribose,” Klin Wochenschr 1986; 64: 1281–1290.

  41. B. M. Patton, “Beneficial Effect of D-ribose in Patients with Myoadenylate Deaminase Deficiency,” The Lancet May 1982; 1701.

  42. C. Salerno, P. D’Eufemia, R. Finocchiaro, M. Celli, A. Spalice, C. Crifo, and O. Giardini, “Effect of D-ribose on Purine Synthesis and Neurological Symptoms in a Patient with Adenylsuccinase Deficiency,” Biochim Biophys Acta 1999; 1453: 135–140.

  43. C. Salerno, M. Celli, R. Finocchiaro, P. D’Eufemia, P. Iannetti, C. Crifo, and O. Giardini, Effect of D-ribose Administration to a Patient with Inherited Defect of Adenylosuccinase. Purine Metabolism in Man IX (New York: Plenum Press, 1998).

  44. D. Pauly and C. Pepine, “D-Ribose as a Supplement for Cardiac Energy Metabolism,” J Cardiovasc Pharmacol Ther 2000; 5 (4): 249–258.

  45. D. Pauly, C. Johnson, and J. A. St. Cyr, “The Benefits of Ribose in Cardiovascular Disease,” Med Hypoth 2003; 60 (2): 149–151.

  46. D. F. Pauly and C. J. Pepine, “Ischemic Heart Disease: Metabolic Approaches to Management,” Clin Cardiol 2004; 27 (8): 439–441.

  47. S. L. Dodd, C. A. Johnson, K. Fernholz, and J. A. St. Cyr. “The Role of Ribose in Human Skeletal Muscle Metabolism,” Med Hypoth 2004; 62 (5): 819–824.

  48. R. Zarzeczny, J. J. Brault, K. A. Abraham, C. R. Hancock, and R. L. Terjung, “Influence of Ribose on Adenine Salvage After Intense Muscle Contractions,” J Appl Physiol 2001; 91: 1775–1781.

  49. J. W. Wallen, M. P. Belanger, and C. Wittnich, “Preischemic Administration of Ribose to Delay the Onset of Irreversible Ischemic Injury and Improve Function: Studies in Normal and Hypertrophied Hearts,” Can J Physiol Pharmacol 2003; 81: 40–47.

  50. R. Wilson, D. MacCarter, and J. St. Cyr, “D-ribose Enhances the Identification of Hibernating Myocardium,” Heart Drug 2003: 3: 61–62.

  51. D. Van Gammeren, D. Faulk, and J. Antonio, “The Effects of Four Weeks of Ribose Supplementation on Body Composition and Exercise Performance in Healthy, Young Male Recreational Bodybuilders: A Double-Blind, Placebo-Controlled Trial,” Curr Ther Res 2002; 63 (8): 486–495.

  52. R. Sharma, M. Munger, S. Litwin, O. Vardeny, D. MacCarter, and J. A. St. Cyr, “D-ribose Improves Doppler TEI Myocardial Performance Index and Maximal Exercise Capacity in Stage C Heart Failure,” J Mol Cell Cardiol 2005; 38 (5): 853.

  53. W. Pliml, T. von Arnim, A. Stablein, H. Hofmann, H. G. Zimmer, and E. Erdmann, “Effects of Ribose on Exercise-
Induced Ischaemia in Stable Coronary Artery Disease,” The Lancet 1992; 340: 507–510.

  54. D. Perkowski, S. Wagner, A. Marcus, and J. St. Cyr, “D-ribose Improves Cardiac Indices in Patients Undergoing “Off” Pump Coronary Arterial Revascularization,” J Surg Res 2007; 173 (2): 295.

  55. C. Muller, H. Zimmer, M. Gross, U. Gresser, I. Brotsack, M. Wehling, and W. Pliml, “Effect of Ribose on Cardiac Adenine Nucleotides in a Donor Model for Heart Transplantation,” Eur J Med Res 1998; 3: 554–558.

  56. G. F. Grant and R. W. Gracey, “Therapeutic Nutraceutical Treatments for Osteoarthritis and Ischemia,” Exp Opin Ther Patents 2000; 10 (1): 1–10.

  57. A. V. Plioplys and S. Plioplys, “Amantadine and L-carnitine Treatment of Chronic Fatigue Syndrome,” Neuropsychobiology 35 (1) (1997): 16–23.

  58. H. Kuratsune, K. Yamaguti, M. Takahashi, et al., “Acylcarnitine Deficiency in Chronic Fatigue Syndrome,” Clinical Infectious Disease 18 (3 supplement 1) (January 1994): S62–S67.

  59. http://www.hsrmagazine.com/hotnews/66h21048207977.html)

  60. P. R. Palan, K. Connell, et al., “Effects of Menopause and Hormone Replacement Therapy on Serum Levels of Coenzyme Q10 and Other Lipid-Soluble Antioxidants,” Biofactors, 2005; 25 (1–4): 61–66.

  61. H. K. Berthold, A. Naini, et al., “Effect of Ezetimibe and/or Simvastatin on Coenzyme Q10 Levels in Plasma: A Randomized Trial,” Drug Saf, 2006; 29 (8): 703–712.

  62. S. Sander, S. I. Coleman, et al., “The Impact of Coenzyme Q10 on Systolic Function in Patients with Chronic Heart Failure,” Journal of Cardiac Failure, 2006; 12 (6): 464–472.

  63. K. A. Weant and K. M. Smith, “The Role of Coenzyme Q10 in Heart Failure,” Ann Pharmacother, 2005; 39 (9): 1522–1526.

  64. K. Folkers, S. Shizukuishi, K. Takemura, et al., “Increase in Levels of IgG in Serum of Patients Treated with Coenzyme Q10,” Research Communications in Chemical Pathology and Pharmacology 38 (2) (1982): 335–338.

  65. K. Folkers, P. Langsjoen, Y. Nara, et al., “Biochemical Deficiencies of Coenzyme Q10 in HIV Infection and Exploratory Treatment,” Biochemical and Biophysical Research Communications 153 (2) (1988): 888–896.